A Phase 1 Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Healthy Volunteers and Patients With Chronic Hepatitis B

Trial Profile

A Phase 1 Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Healthy Volunteers and Patients With Chronic Hepatitis B

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs NVR 3778 (Primary) ; Peginterferon alfa-2a
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Novira Therapeutics
  • Most Recent Events

    • 16 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 04 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 May 2016 as reported by ClinicalTrials.gov.
    • 04 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 May 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top